contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


carlsquare-analysuppdatering-elicera-therapeutics-hojer-insatserna-efter-framsteg

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Elicera Therapeutics

Carlsquare Equity Research har publicerat en analysuppdatering efter rapporten för kv1 2026 och pågående företrädesemission.Läs hela analysen här.Om CarlsquareCarlsquare is a global research...

<div class="mfn-body">Carlsquare Equity Research har publicerat en analysuppdatering efter rapporten för kv1 2026 och pågående företrädesemission.<a href="https://carlsquare.com/sv/analys-elicera-therapeutics-hojer-insatserna-efter-framsteg/" rel="noopener">Läs hela analysen här.</a></div><div class="mfn-footer mfn-about mfn-ff317aff455d">Om Carlsquare<hr>Carlsquare is a global research firm and financial advisor focusing on M&amp;A, Equity Research and Growth Equity. Carlsquare has 170 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience in the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. <a href="https://www.carlsquare.com/" rel="noopener">Read more</a><a href="http://www.carlsquare.com" rel="noopener">www.carlsquare.com</a></div><div class="mfn-footer mfn-contacts mfn-6ca94a02479e">Kontakter<hr>MARKUS AUGUSTSSON Head of Equity Research <a href="mailto:markus.augustsson@carlsquare.com" rel="noopener">markus.augustsson@carlsquare.com</a> +46 (0)76 235 03 20 &nbsp; NIKLAS ELMHAMMER Senior Equity Analyst <a href="mailto:niklas.elmhammer@carlsquare.com" rel="noopener">niklas.elmhammer@carlsquare.com</a> +46 (0)70 898 39 59</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Bifogade filer<hr><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/6e9b87ef-dc25-4453-b000-e07a2903514d/analysuppdatering-elicera-therapeutics-hojer-insatserna-efter-framsteg.pdf" rel="noopener">Analysuppdatering Elicera Therapeutics: Höjer insatserna efter framsteg</a></div>

Carlsquare: Analysuppdatering Elicera Therapeutics: Höjer insatserna efter framsteg

Intervjuer i samband med Stockholm Corporate Finance 17:e Kapitalmarknadsdagar Life Science 2026

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Return on capital (ROE, ROI, ROIC, RONIC)

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Saab

Bittium

W5 Solutions

Scandinavian Astor Group

MilDef Group

INVISIO

Argo Defence Group

European Defense Sector Outlook: Long-cycle rearmament drives fundamentals, but stretched valuations force selectivity